Shares of Moderna Inc (MRNA) are trading 6% higher at a price of $138.73 at the time of this writing. While it's a mildly optimistic day for the Health Care sector in general, the stock is outrunning it's peers.

- The company is in talks with the Chinese government about supplying COVID-19 vaccines, but no decision has been made yet
- The company's CEO Stephane Bancel said there is about a 20% probability that a "problematic" variant of the virus could emerge this winter
- The Japanese regulator has approved a partial change to Moderna's new drug application for its omicron-targeting COVID booster

Moderna Inc has been trading between a 52-week high of $458.5 and a 52-week low of $115.61. The stock has a market cap of $55.2 Billion.

Moderna, Inc is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It focuses on drug discovery, drug development, and vaccine technologies based on messenger RNA.

Moderna Stock News and Forecast: MRNA drops, but China could provide a catalyst
FXStreet 09-14-22

Top Financial Stories Wednesday, September 14: Multiple Antitrust Setbacks For Google, Bitcoin Crashes, Visa Finds New Gun Control System Ineffective And More…
Benzinga 09-14-22

Moderna PT Lowered to $150 at Argus
Investing.com 09-14-22

COVID-19 Vaccine Supply To China? Moderna CEO Says Capacity Available
Benzinga 09-14-22

What''s Moderna''s Next Billion-Dollar Market? The Answer May Surprise You.
The Motley Fool 09-14-22